Charles River Laboratories International Inc (CRL) Actualités

Form 8-K - Current report

Charles River Introduces Global Biotech Incubator Program

Program offers biotechnology developers access to extensive scientific expertise and a wide ecosystem of discovery, development and manufacturing...

Charles River Laboratories to Present at Evercore ISI Investor Conference

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 7th Annual Evercore ISI HealthCONx...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Charles River Laboratories to Present at UBS and Jefferies Conferences

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the UBS Global Healthcare Conference on...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Charles River Laboratories Announces Third-Quarter 2024 Results

– Third-Quarter Revenue of $1.01 Billion – – Third-Quarter GAAP Earnings per Share of $1.33 and Non-GAAP Earnings per Share of $2.59 – –...

Charles River Launches New Retrogenix® Non-Human Protein Library

First-in-class in vitro library assesses off-target binding to de-risk in vivo studies Charles River Laboratories International, Inc. (NYSE:...

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call

Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before...

Charles River Provides Translational Expertise at Neuroscience 2024

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18...